Monitoring Abacavir (cas 136470-78-5) bioactivation in humans: Screening for an aldehyde metabolite

Add time:09/10/2019    Source:sciencedirect.com

The anti-HIV drug Abacavir (cas 136470-78-5) is associated with idiosyncratic hypersensitivity reactions and cardiotoxicity. Although the mechanism underlying abacavir-toxicity is not fully understood, drug bioactivation to reactive metabolites may be involved. This work was aimed at identifying abacavir–protein adducts in the hemoglobin of HIV patients as biomarkers of abacavir bioactivation and protein modification. The protocol received prior approval from the Hospital Ethics Committee, patients gave their written informed consent and adherence was controlled through a questionnaire. Abacavir-derived Edman adducts with the N-terminal valine of hemoglobin were analyzed by an established liquid chromatography–electrospray ionization–tandem mass spectrometry method. Abacavir–valine adducts were detected in three out of ten patients. This work represents the first evidence of abacavir–protein adduct formation in humans. The data confirm the ability of abacavir to modify self-proteins and suggest that the molecular mechanism(s) of some abacavir-induced adverse reactions may require bioactivation.

We also recommend Trading Suppliers and Manufacturers of Abacavir (cas 136470-78-5). Pls Click Website Link as below: cas 136470-78-5 suppliers

Prev:Effect of drug efflux transporters on placental transport of antiretroviral agent Abacavir (cas 136470-78-5)
Next:Synthesis of novel nicotinohydrazide and (1,3,4-oxadiazol-2-yl)-6-(trifluoromethyl)pyridine derivatives as potential anticancer agents)